Therefore, it has been proposed that POLE-mutated tumours might need less aggressive treatment and, if they do need treatment, they might be eligible for checkpoint inhibitors, due to the highly immunogenic character of these tumours [3,20]. This evidence concerns the gene POLE and neoplasm.